The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial

Abstract The vasopressin V2 receptor antagonist tolvaptan delays the progression of autosomal dominant polycystic kidney disease (ADPKD). However, some patients discontinue tolvaptan because of severe adverse aquaretic events. This open-label, randomized, controlled, counterbalanced, crossover trial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kiyotaka Uchiyama, Chigusa Kitayama, Akane Yanai, Yoshitaka Ishibashi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/edc0d792befa40818f671fc0aec063c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:edc0d792befa40818f671fc0aec063c5
record_format	dspace
spelling	oai:doaj.org-article:edc0d792befa40818f671fc0aec063c52021-12-02T16:37:37ZThe effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial10.1038/s41598-021-97113-w2045-2322https://doaj.org/article/edc0d792befa40818f671fc0aec063c52021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97113-whttps://doaj.org/toc/2045-2322Abstract The vasopressin V2 receptor antagonist tolvaptan delays the progression of autosomal dominant polycystic kidney disease (ADPKD). However, some patients discontinue tolvaptan because of severe adverse aquaretic events. This open-label, randomized, controlled, counterbalanced, crossover trial investigated the effects of trichlormethiazide, a thiazide diuretic, in patients with ADPKD receiving tolvaptan (n = 10) who randomly received antihypertensive therapy with or without trichlormethiazide for 12 weeks. The primary and secondary outcomes included amount and osmolarity of 24-h urine and health-related quality-of-life (HRQOL) parameters assessed by the Kidney Disease Quality of Life-Short Form questionnaire, renal function slope, and plasma/urinary biomarkers associated with disease progression. There was a significant reduction in urine volume (3348 ± 584 vs. 4255 ± 739 mL; P < 0.001) and a significant increase in urinary osmolarity (182.5 ± 38.1 vs. 141.5 ± 38.1 mOsm; P = 0.001) in patients treated with trichlormethiazide. Moreover, trichlormethiazide improved the following HRQOL subscales: effects of kidney disease, sleep, emotional role functioning, social functioning, and role/social component summary. No significant differences were noted in renal function slope or plasma/urinary biomarkers between patients treated with and without trichlormethiazide. In patients with ADPKD treated with tolvaptan, trichlormethiazide may improve tolvaptan tolerability and HRQOL parameters.Kiyotaka UchiyamaChigusa KitayamaAkane YanaiYoshitaka IshibashiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kiyotaka Uchiyama Chigusa Kitayama Akane Yanai Yoshitaka Ishibashi The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
description	Abstract The vasopressin V2 receptor antagonist tolvaptan delays the progression of autosomal dominant polycystic kidney disease (ADPKD). However, some patients discontinue tolvaptan because of severe adverse aquaretic events. This open-label, randomized, controlled, counterbalanced, crossover trial investigated the effects of trichlormethiazide, a thiazide diuretic, in patients with ADPKD receiving tolvaptan (n = 10) who randomly received antihypertensive therapy with or without trichlormethiazide for 12 weeks. The primary and secondary outcomes included amount and osmolarity of 24-h urine and health-related quality-of-life (HRQOL) parameters assessed by the Kidney Disease Quality of Life-Short Form questionnaire, renal function slope, and plasma/urinary biomarkers associated with disease progression. There was a significant reduction in urine volume (3348 ± 584 vs. 4255 ± 739 mL; P < 0.001) and a significant increase in urinary osmolarity (182.5 ± 38.1 vs. 141.5 ± 38.1 mOsm; P = 0.001) in patients treated with trichlormethiazide. Moreover, trichlormethiazide improved the following HRQOL subscales: effects of kidney disease, sleep, emotional role functioning, social functioning, and role/social component summary. No significant differences were noted in renal function slope or plasma/urinary biomarkers between patients treated with and without trichlormethiazide. In patients with ADPKD treated with tolvaptan, trichlormethiazide may improve tolvaptan tolerability and HRQOL parameters.
format	article
author	Kiyotaka Uchiyama Chigusa Kitayama Akane Yanai Yoshitaka Ishibashi
author_facet	Kiyotaka Uchiyama Chigusa Kitayama Akane Yanai Yoshitaka Ishibashi
author_sort	Kiyotaka Uchiyama
title	The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
title_short	The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
title_full	The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
title_fullStr	The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
title_full_unstemmed	The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
title_sort	effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/edc0d792befa40818f671fc0aec063c5
work_keys_str_mv	AT kiyotakauchiyama theeffectoftrichlormethiazideinautosomaldominantpolycystickidneydiseasepatientsreceivingtolvaptanarandomizedcrossovercontrolledtrial AT chigusakitayama theeffectoftrichlormethiazideinautosomaldominantpolycystickidneydiseasepatientsreceivingtolvaptanarandomizedcrossovercontrolledtrial AT akaneyanai theeffectoftrichlormethiazideinautosomaldominantpolycystickidneydiseasepatientsreceivingtolvaptanarandomizedcrossovercontrolledtrial AT yoshitakaishibashi theeffectoftrichlormethiazideinautosomaldominantpolycystickidneydiseasepatientsreceivingtolvaptanarandomizedcrossovercontrolledtrial AT kiyotakauchiyama effectoftrichlormethiazideinautosomaldominantpolycystickidneydiseasepatientsreceivingtolvaptanarandomizedcrossovercontrolledtrial AT chigusakitayama effectoftrichlormethiazideinautosomaldominantpolycystickidneydiseasepatientsreceivingtolvaptanarandomizedcrossovercontrolledtrial AT akaneyanai effectoftrichlormethiazideinautosomaldominantpolycystickidneydiseasepatientsreceivingtolvaptanarandomizedcrossovercontrolledtrial AT yoshitakaishibashi effectoftrichlormethiazideinautosomaldominantpolycystickidneydiseasepatientsreceivingtolvaptanarandomizedcrossovercontrolledtrial
_version_	1718383667051495424

The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial

Ejemplares similares